

# Accepted Manuscript

Synthesis, carbonic anhydrase inhibition and cytotoxic activity of novel chromone-based sulfonamide derivatives

Fadi M. Awadallah, Tamer A. El-Waei, Mona M. Hanna, Safinaz E. Abbas, Mariangela Ceruso, Beyza Ecem Oz, Ozen Ozensoy Guler, Claudiu T. Supuran



PII: S0223-5234(15)00292-5

DOI: [10.1016/j.ejmech.2015.04.033](https://doi.org/10.1016/j.ejmech.2015.04.033)

Reference: EJMECH 7848

To appear in: *European Journal of Medicinal Chemistry*


Received Date: 2 January 2015

Revised Date: 31 March 2015


Accepted Date: 14 April 2015

Please cite this article as: F.M. Awadallah, T.A. El-Waei, M.M. Hanna, S.E. Abbas, M. Ceruso, B.E. Oz, O.O. Guler, C.T. Supuran, Synthesis, carbonic anhydrase inhibition and cytotoxic activity of novel chromone-based sulfonamide derivatives, *European Journal of Medicinal Chemistry* (2015), doi: 10.1016/j.ejmech.2015.04.033.


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Graphical abstract:**


General formula A



General formula B



General formula C



General formula D

Compound **4a** (general formula B; R=H) has  $IC_{50}$  of 0.72 and 0.50  $\mu$ M against MCF-7 and A-549 cells, respectively. It has  $K_i$  of 29.75 and 4.54 nM on hCA IX and XII, respectively. It raises the % of early apoptotic cells to 94.12 and 74.77% in breast and lung cells, respectively.

## Synthesis, carbonic anhydrase inhibition and cytotoxic activity of novel chromone-based sulfonamide derivatives

Fadi M. Awadallah,<sup>a\*</sup> Tamer A. El-Waei,<sup>a</sup> Mona M. Hanna,<sup>a</sup> Safinaz E. Abbas,<sup>a</sup> Mariangela Ceruso,<sup>b</sup> Beyza Ecem Oz,<sup>b,c</sup> Ozen Ozensoy Guler,<sup>b,c</sup> Claudiu T. Supuran<sup>b\*</sup>

<sup>a</sup> *Pharmaceutical Chemistry department, Faculty of Pharmacy, Cairo University, Kasr El-Eini street, 11562, Cairo Egypt*

<sup>b</sup> *University of Florence, Neurofarba Department, Via Ugo Schiff 6, Polo Scientifico, 50019, Sesto Fiorentino (Firenze) Italy*

<sup>c</sup> *Yildirim Beyazit University Faculty of Medicine Department of Medical Biology, Cinnah Campus Ankara, Turkey*

### Abstract.

Four series of sulfonamides incorporating chromone moieties were synthesized and assessed for their cytotoxic activity against MCF-7 and A-549 cell lines, considering the fact that some of these tumors overexpress isoforms of carbonic anhydrase (CA, EC 4.2.1.1) which is inhibited by sulfonamides. Most new sulfonamides showed weak inhibitory activity against the offtarget, cytosolic isoforms hCA I, II but effectively inhibited the tumor-associated hCA IX and XII. The most active compounds featured a primary SO<sub>2</sub>NH<sub>2</sub> group and were active in the low micromolar range against MCF-7 and A-549 cell lines. Compound **4a** showed IC<sub>50</sub> of 0.72 and 0.50 μM against MCF-7 and A-549 cell lines, respectively, and was further evaluated for its proapoptotic activity which proved enhanced in both tumor types.

**Keywords:** Chromone; sulfonamide; breast cancer; lung cancer; carbonic anhydrase.

---

\*Corresponding authors: E-mail address :[fadi\\_mae@hotmail.com](mailto:fadi_mae@hotmail.com) (F.M. Awadallah); Telephone/fax: +39-055-4573729, E-mail:[claudiu.supuran@unifi.it](mailto:claudiu.supuran@unifi.it) (C.T. Supuran)

## 1. Introduction.

Chromones are naturally occurring oxygen containing heterocyclic compounds that are widely distributed in plant kingdom and form the basic nucleus of important compounds such as anthocyanin and flavonoids. Chromones are also well known for their antimicrobial [1,2], antitumor [3,4], and antiviral [5,6] activities. Chromone-3-carboxaldehyde are important synthons in the synthesis of chromone-based bioactive molecules. [7,8]. They are widely used due to their ease of preparation and modification via Vilsmeier Haack reaction [9,10].

The clinical and medicinal importance of sulfonamides is well documented. The sulfonamide moiety ( $-\text{SO}_2\text{NH-R}$ ) is an active pharmacophore, exhibiting a wide variety of pharmacological activities such as antimicrobial, antimalarial, insulin-releasing antidiabetic, anti-HIV, high ceiling diuretic, antithyroid, and antitumor activities [11-15]. Among the broad spectrum of activities elicited by sulfonamides is their role as inhibitors of the zinc containing metalloenzyme carbonic anhydrase (CA). Many sulfonamide CA inhibitors have been used as therapeutic agents against various diseases including glaucoma, gastro-duodenal ulcers, acid-base disequilibria, and various neurological disorders [16-19].

Carbonic anhydrases (CAs, EC 4.2.1.1) are a group of metalloenzymes that are involved in pH buffering of extra- and intracellular spaces by catalyzing the reversible hydration of carbon dioxide (cellular waste product) to bicarbonate and a proton [20-25]. This family of enzymes comprises six genetic families, i.e.,  $\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\delta$ ,  $\zeta$  and  $\eta$ -classes. Among the 16 known human (h) CA isoforms belonging to class  $\alpha$ , the human cytosolic isoforms hCA I and hCA II are ubiquitous in the body and are targets for anticonvulsant, diuretic and anti-glaucoma drugs. On the other hand, the transmembrane isoforms hCA IX and hCA XII, possessing an extracellular active site, are associated with some types of cancers being induced by tumor hypoxia. This being the case, these two isoforms justifiably represent good candidates for antitumor drug design, with one sulfonamide CA IX/XII inhibitor currently in Phase I clinical trials for the treatment of primary tumors/metastases overexpressing these enzymes [26-28].

In addition to the aforementioned facts, literature revealed combined chromone-sulfonamides hybrids as potent antitumor and CA inhibitors as exemplified by compound **I** and **II** which featured a chromone nucleus linked to a sulfonamide moiety either through a methine ( $=\text{CH-}$ ) group; or through a heterocyclic pyrimidine spacer [29], respectively (Figure 1). Accordingly, with the goal of producing new antitumor agents, a hybrid pharmacophoric approach was adopted in the design of the target compounds in which the chromone and an

appropriately *N*-(un)substituted sulfonamide moieties were combined via a methine spacer (General formula A) in one molecule. Further investigation was performed by including the reduced methyleneamino (-CH<sub>2</sub>NH-) linker instead of the methineamino one (=CH-NH-) in order to impart structure flexibility (General formula B). Another group of target compounds were designed in such a way to separate the chromone and the sulfonamide pharmacophores through incorporation of a heterocyclic spacer. Searching for suitable heterocyclic rings of antitumor importance unveiled the potential activity of the thiazolinone [30-32] and its isosteric imidazolinone moieties [33,34]. Consequently, and motivated by the positive biological activities of many derivatives incorporating these heterocyclic rings, compounds of general formula C and D were synthesized (Figure 2). The new compounds were screened *in vitro* against two cell lines: breast MCF-7 and lung A-549. Furthermore, the derivatives that showed remarkable activity profile were tested for their CA inhibitory activity.

## 2. Discussion.

### 2.1. Chemistry.

The key starting compound, chromone-3-carboxaldehyde **2**, was prepared from 2-hydroxyacetophenone **1**, dimethylformamide (DMF) and phosphorous oxychloride according to the Vilsmeier-Haack reaction [35,36]. The first series of target compounds **3a-f** was synthesized via reacting **2** with the appropriate sulfonamide in ethanol in the presence of catalytic amount of glacial acetic acid. The expected Schiff's base derivatives were not obtained, but rather the enamine adducts **3a-f** were afforded. This could be explained on the basis of the presence of a very reactive electron deficient center at C2 of the chromone nucleus which facilitated the nucleophilic attack of an ethanol molecule (solvent) that underwent addition on the C2-C3 double bond. In addition, it was observed that performing the reaction in different solvents such as methanol or *n*-butanol resulted in the 2-methoxy and 2-*n*-butyloxy derivatives, respectively, as confirmed by spectral data. Moreover, literature provided similar explanation for this unexpected reaction [37, 38, 39]. Trials to carry out the reaction using acetic acid as a solvent or aprotic solvents such as toluene or benzene gave a mixture of two products that were difficult to be separated. The major product consisted of an enamine adduct in which a second molecule of the sulfonamide acted as nucleophile that underwent addition to the C2-C3 olefinic bond of the chromone ring. The minor product was the expected Schiff's base. Similar unexpected reactions were also reported in literature [1,40] (Scheme 1).

The second series of target compounds was obtained by reducing the enamine adducts **3a-f** with sodium borohydride in ethanol which furnished the methylene-amino derivatives **4a-f** together with the elimination of the ethoxy group at C2 of the chromone ring (Scheme 1).

The chromone-sulfonamide hybrids incorporating a thiazolinone spacer **7a-f** were obtained by reacting the chromone-3-carboxaldehyde **2** with the appropriate thiazolinone-bearing sulfonamide derivatives **6a-f**. This was achieved by reaction of the appropriate sulfonamide with chloroacetyl chloride in DMF according to the literature procedures to give the *N*<sup>4</sup>-chloroacetamides **5a-f** [41-44]. The latter were reacted with ammonium thiocyanate to undergo intramolecular cyclization with elimination of ammonium chloride to produce the corresponding thiazolinone intermediates **6a-f**. Knoevenagel condensation of the aldehyde **2** with the active methylene protons of the intermediates **6a-f** was performed in glacial acetic acid in the presence of anhydrous sodium acetate to produce the third group of target compounds **7a-f** (Scheme 2).

Finally, the last series of compounds comprising the 4-oxo-imidazolyl-benzenesulfonamides **10a-f** and **11a-f** were prepared via reaction of the appropriate oxazolone **9a,b** with the appropriate sulfonamide as illustrated in Scheme 3. The intermediates **9a,b** were obtained by benzoylation of glycine with the appropriate benzoyl chloride in sodium hydroxide solution (10%) to afford **8a,b** [45,46], followed by Erlenmeyer cyclocondensation reaction with the aldehyde **2** in acetic anhydride in the presence of anhydrous sodium acetate [47]. The target imidazolinones **10a-f** and **11a-f** were obtained by the reaction of the corresponding **9a,b** with the appropriate sulfonamide in glacial acetic acid and anhydrous sodium acetate.

## 2.2. *In vitro* cytotoxic activity.

All target compounds were screened *in vitro* for their cytotoxic activity against breast (MCF-7) and lung (A-549) cells using the sulforhodamine B (SRB) assay as described by Skehan et al. [48]. IC<sub>50</sub> values (μM) were calculated from the mean value of three separate experiments. Doxorubicin (DOX) was used as a positive control. Results were listed in Table 1. Concerning the activity against the breast cell line, most compounds of the first series, **3a-f**, showed higher activity than doxorubicin (IC<sub>50</sub> = 22.19-30.06 μM) except compounds **3d** and **3e**. The reduced derivatives **4a-f** demonstrated a decrease in activity compared to compounds **3a-f**, except for compound **4a** that exhibited a highly potent activity in a submicromolar value (IC<sub>50</sub> = 0.72 μM). Substitution of the aminomethine or methylamino spacer by thiazolinone or imidazolinone moieties as in compounds **7a-f**, **10a-f** and **11a-f**, respectively, was not in favor

of activity except for the  $N^4$ -unsubstituted-sulfonamide derivatives **7a**, **10a** and **11a** which showed increase in activity ( $IC_{50}$ = 8.91, 11.50 and 24.31  $\mu$ M, respectively).

As per the activity of the tested compounds against the lung A-549 cell line, all compounds were less potent than doxorubicin except for compounds **4a**, **7a**, **10a** and **11a** ( $IC_{50}$ = 0.50, 2.23, 1.73 and 13.77  $\mu$ M, respectively). Compound **4e** was almost equipotent to doxorubicin ( $IC_{50}$ = 25.59  $\mu$ M).

Regarding the effect of the  $N^4$ -substitution on the sulfonamide moiety, it could be clearly observed that the unsubstituted derivatives were the most potent within all series. Compound **4a** represented a promising candidate molecule being active against both cell lines in the submicromolar range.

### 2.3. Carbonic anhydrase inhibition.

The CA inhibitory ability of some selected sulfonamides that demonstrated good activity profile in the in vitro antitumor assay was assessed against the cytosolic isoforms hCA I and II as well as the membrane associated isoforms hCA IX and XII employing a stopped flow assay method [49] and the results are shown in Table 2. The well known CA inhibitor acetazolamide (AZA) was used as the reference drug for this assay. Data obtained from the CA inhibition assay revealed that the tested compounds were selective to the tumor associated isoforms hCA IX and hCA XII with activity in the nanomolar range. Very weak or no activity at all was observed against hCA I and II, except for compound **7a** (hCA II  $K_i$ = 12.95 nM). This selectivity could be considered a desirable attribute for cytotoxic agents to guard against the occurrence of untoward side effects. The hCA IX isoform was highly inhibited by compounds **3b**, **3e**, **3f**, **7a**, **10a** and **11a** ( $K_i$ = 14.26-23.84 nM) surpassing the activity of AZA. The rest of the compounds were either equipotent or slightly less potent than AZA. With regards to the profiling assay against hCA XII, only two compounds, **4a** and **10a**, displayed slightly higher activity than AZA ( $K_i$ = 4.54 and 5.23 nM, respectively). Compounds of moderate potency against hCA XII were **4b**, **7a**, **10b** and **11a** ( $K_i$ = 6.24-10.76 nM). Also, it could be noted that the most active compounds on hCA IX (**7a** and **11a**) and hCA XII (**4a** and **10a**) were those derivatives whose sulfonamide pharmacophore possessed a free sulfamoyl group.

### 2.4. Apoptosis study.

To examine the involvement of apoptosis in the cytotoxic activity of the new sulfonamide derivatives, MCF-7 and A-549 cells were incubated with the most potent compound **4a** at its  $IC_{50}$  concentration for 24 h. The percentage of apoptotic cells were

determined by Annexin V-FITC/PI staining and the stained cells were detected by flow cytometry (Figure 3). The results showed that **4a** induced apoptosis in MCF-7 cells where the percentage of early apoptotic cells reached 94.12%; whereas, the percentage of early apoptotic cells attained 74.77 % in A-549 cells. The percentage of early apoptotic cells was markedly elevated as a function of concentration of the tested agent from 0.54 % to 46.85%.

### 3. Conclusion.

Four series of new chromone-based sulfonamide derivatives were synthesized and tested for their in vitro cytotoxic activity against breast (MCF-7) and lung (A-549) cell lines. Compared to doxorubicin, the tested against breast cancer cell lines than lung cancer cell lines. Compounds in which the chromone and sulfonamide pharmacophores were separated by a small spacer group such as =CH-N- or -CH<sub>2</sub>NH-, **3a-f** and **4a-f**, respectively, were more potent than those more widely separated by a heterocyclic thiazolinone or imidazolinone rings, **7a-f**, **10a-f** and **11a-f**, respectively. Also, it was noted that derivatives possessing a free sulfamoyl group, **4a**, **7a**, **10a** and **11a** were the most potent. Compounds showing high activity profile in the in vitro cell line screening were further evaluated for their carbonic anhydrase inhibitory activity against hCA I, II, IX and XII isoforms. The profiling enzyme assay revealed that the tested compounds were selective to the tumor associated isoforms hCA IX and XII in the nanomolar range, and that the compounds that exhibited activity higher than that expressed by acetazolamide were those having a free sulfamoyl group. Finally, compound **4a**, which possessed the highest activity against the tested cell lines, was further investigated for its proapoptotic activity where induction of apoptosis was markedly observed in both cancer cell types. In conclusion, it could be claimed that compound **4a**, denoting IC<sub>50</sub> of 0.72 and 0.50  $\mu$ M against MCF-7 and A-549 cells; and a K<sub>i</sub> of 29.75 and 4.54 nM on hCA IX and XII; and which raised the % of early apoptotic cells to 94.12 and 74.77 % in breast and lung cells, respectively, could be a promising lead for future investigation.

### 4. Experimental.

#### 4.1. Chemistry:

Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. TLC was monitored on FLUKA silica gel TLC aluminium cards (0.2 mm thickness) with fluorescent indicator 254 nm using chloroform: methanol (9.5:0.5) as eluent. Melting points were performed on Stuart SMP3 version 5 digital melting

point apparatus and were uncorrected. Elemental microanalyses were performed at the Microanalytical Center, at the Regional Center for Mycology and Biotechnology, Al-Azhar University.  $^1\text{H}$  NMR spectra were measured in dimethylsulphoxide ( $\text{DMSO-}d_6$ ) on a Varian Mercury VX-300 MHz spectrophotometer or Bruker AVANCE III Nano Bay 400 MHz FT-NMR spectrophotometer. Chemical Shifts were reported in  $\delta$  as parts per million (ppm) downfield from tetramethylsilane (TMS) as internal standard.  $^{13}\text{C}$  NMR spectra were recorded on Bruker AVANCE III Nano Bay 400 MHz FT-NMR spectrophotometer at 100 MHz. Mass spectra were performed on Fennigan MAT, SSQ 7000 mass spectrophotometer at 70eV. Infrared Spectra were recorded on Shimadzu FT-IR 8400S spectrophotometer (Shimadzu, Kyoto, Japan), and expressed in wave number ( $\text{cm}^{-1}$ ), using potassium bromide discs.

Compounds **2** [35,36], **3a** [28], **3c** [39], **5a-f** [40-43], **6a** [49], **6f** [50], **8a,b** [44,45], **9a,b** [46] were prepared according to the reported procedures.

#### 4. Experimental:

##### 4.1. General method for the synthesis of compounds (**3a-f**)

A solution of chromone-3-carboxaldehyde **2** (1.74 g, 10 mmol), the appropriate sulfonamide (10 mmol) and glacial acetic acid (0.5 mL) in absolute ethanol (10 mL) was refluxed for 3.5 h and kept overnight at room temperature. The separated solid was filtered off and crystallized from a mixture of ethanol:acetone mixture (1:1).

##### 4.1.1. 4-(((2-Ethoxy-4-oxochroman-3-ylidene)methyl)amino)benzenesulfonamide (**3a**)

(Yield: 85 %, m.p. 158-160 °C as reported) [28].

##### 4.1.2. 4-(((2-Ethoxy-4-oxochroman-3-ylidene)methyl)amino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide (**3b**)

Yield: 88%; m.p. 208–211 °C. IR ( $\text{cm}^{-1}$ ): 3365 (NH), 3061 (aromatic CH), 2974 (aliphatic CH), 1649 (C=O), 1284 ( $\text{SO}_2^{\text{asym}}$ ), 1165 ( $\text{SO}_2^{\text{sym}}$ ).  $^1\text{H}$  NMR (400 MHz)  $\delta$ : 1.07 (t, 3H,  $J=7.0$  Hz,  $\text{CH}_2\text{CH}_3$ ), 2.30 (s, 3H,  $\text{CH}_3$ ), 3.81 (q, 2H,  $J=7.0$  Hz,  $\text{CH}_2\text{CH}_3$ ), 5.94 (s, 1H, CH-2 chromone), 6.15 (s, 1H, CH, isoxazole), 6.69 (d, 2H,  $J=8.7$  Hz, CH-3, CH-5 of phenyl), 7.08 (d, 1H,  $J=8.2$  Hz, CH-8 chromone), 7.13 (t, 1H,  $J=8.5$  Hz, CH-6 chromone), 7.51 (d, 2H,  $J=8.7$  Hz, CH-2, CH-6 of phenyl), 7.58 (d, 1H,  $J=8.8$  Hz, CH-5 chromone), 7.86 (t, 1H,  $J=8.7$  Hz, CH-7 chromone), 8.12 (d, 1H,  $J=12.0$ , CH enamine), 11.35 (s, 1H,  $\text{SO}_2\text{NH}$ , exchanged by  $\text{D}_2\text{O}$ ), 11.73 (d, 1H,  $J=12.0$ , NH, exchanged with  $\text{D}_2\text{O}$ ).  $^{13}\text{C}$ -NMR  $\delta$ : 12.4 ( $\text{CH}_3$  of isoxazole ring), 15.3 ( $\text{CH}_3$ ,  $-\text{OCH}_2\text{CH}_3$ ), 63.6 ( $\text{CH}_2$ ,  $-\text{OCH}_2\text{CH}_3$ ), 95.6 (C-4 of isoxazole), 100.2 (C-2 of

chromanone), 105.8 (C-3+C-5 of phenyl), 113.0 (C-8 of chromanone), 117.0 (C-3 of chromanone), 120.4, 122.5, 124.4, 125.7, 126.2, 127.2, 129.2, 133.7, 135.5, 136.7 (aromatic Cs), 153.5 (C-3 of isoxazole), 157.8 (C-8a of chromanone), 170.5 (C-5 of isoxazole), 181.3 (C-4 of chromanone). EI-MS  $m/z$  (%): 455.38 ( $M^+$ , 22.2%). Anal. Calcd. for  $C_{22}H_{21}N_3O_6S$  (455.48): C, 58.01; H, 4.65; N, 9.23. Found: C, 58.03; H, 4.67; N, 9.29.

4.1.3. 4-(((2-Ethoxy-4-oxochroman-3-ylidene)methyl)amino)-N-(pyrimidin-2-yl)benzenesulfonamide (**3c**) [39]

Yield: 73%; m.p. 244–245°C. IR ( $cm^{-1}$ ): 3346 (NH), 3034 (aromatic CH), 2935 (aliphatic CH), 1653(C=O), 1280 ( $SO_2^{asym}$ ), 1157 ( $SO_2^{sym}$ ).  $^1H$  NMR (300MHz)  $\delta$ : 1.05 (t, 3H,  $J=7.0$  Hz,  $CH_2CH_3$ ), 3.67 (q, 2H,  $J=7.0$  Hz,  $CH_2CH_3$ ), 5.94 (s, 1H, CH-2, chromone), 7.03–7.16 (m, 3H, ArH), 7.52–7.82 (m, 4H, ArH), 7.85–7.97 (m, 5H, ArH), 8.10 (d, 1H,  $J=12.3$  Hz, CH enamine), 11.74 (d, 1H,  $J=12.6$  Hz, NH, exchanged with  $D_2O$ ). Anal. Calcd. for  $C_{22}H_{20}N_4O_5S$  (452.49): C, 58.40; H, 4.46; N, 12.38. Found: C, 58.52; H, 4.48; N, 12.38.

4.1.4. N-(4,6-Dimethylpyrimidin-2-yl)-4-(((2-ethoxy-4-oxochroman-3-ylidene)methyl)amino)benzenesulfonamide (**3d**)

Yield: 75%; m.p. 288–290. IR ( $cm^{-1}$ ): 3230 (NH), 3082 (aromatic CH), 2974 (aliphatic CH), 1651(C=O), 1280( $SO_2^{asym}$ ), 1155 ( $SO_2^{sym}$ ).  $^1H$  NMR (400MHz)  $\delta$ : 1.08 (t, 3H,  $J=7.2$  Hz,  $CH_2CH_3$ ), 2.26 (s, 6H, 2 $CH_3$ ), 3.67 (q, 2H,  $J=7.2$  Hz,  $CH_2CH_3$ ), 5.95 (s, 1H, CH-2, chromone), 6.77 (s, 1H, CH, pyrimidine), 7.05–7.16 (m, 2H, ArH), 7.44–7.57 (m, 3H, ArH), 7.82–7.98 (m, 4H, ArH), 8.13 (d, 1H,  $J=12.0$  Hz, CH enamine), 11.76 (d, 1H,  $J=12.0$  Hz, NH, exchanged with  $D_2O$ ).  $^{13}C$ -NMR  $\delta$ : 15.4 ( $CH_3$ ), 63.5 ( $CH_2$ ), 100.3 (C-2 of chromanone), 105.5 (C-5 of diazine), 116.0 (C-3 + C-5 of phenyl), 118.5 (C-8 of chromanone), 122.4, 125.7, 130.4, 130.6, 135.1, 135.2, 138.9 (aromatic Cs), 143.6 (methine), 144.3 (C-4 of phenyl), 156.2 (C-8a of chromanone), 156.6 (C-4 + C-6 of diazine), 167.8 (C-2 of diazine), 181.1 (C-4 of chromanone). EI-MS  $m/z$  (%): 480.5 ( $M^+$ , 0.1%). Anal. Calcd. for  $C_{24}H_{24}N_4O_5S$  (480.54): C, 59.99; H, 5.03; N, 11.66. Found: C, 60.08; H, 5.07; N, 11.79.

4.1.5. 4-(((2-Ethoxy-4-oxochroman-3-ylidene)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide (**3e**)

Yield: 80%; m.p. 284–288°C. IR ( $cm^{-1}$ ): 3118 (NH), 3012 (aromatic CH), 2972 (aliphatic CH), 1658(C=O), 1278( $SO_2^{asym}$ ), 1147 ( $SO_2^{sym}$ ).  $^1H$  NMR (400MHz)  $\delta$ : 1.07 (t, 3H,  $J=7.1$  Hz,  $CH_2CH_3$ ), 3.68 (q, 2H,  $J=7.1$  Hz,  $CH_2CH_3$ ), 5.95 (s, 1H, CH-2, chromone), 6.45–6.54 (m, 1H, ArH), 6.82–7.05 (m, 3H, ArH), 7.11–7.50 (m, 3H, ArH), 7.61–7.82 (m, 3H, ArH),

8.06 (d, 1H,  $J=12.0$  Hz, CH enamine), 11.77 (d, 1H,  $J=12.0$  Hz, NH, exchanged by D<sub>2</sub>O), 12.72 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR  $\delta$ : 15.4 (CH<sub>3</sub>), 63.5 (CH<sub>2</sub>), 100.3 (C-2 of chromanone), 105.3 (C-5 of thiazole), 108.6 (C-3+C-5 of phenyl), 116.9 (C-8 of chromanone), 118.5 (C-3 of chromanone), 122.3, 123.0, 124.9, 126.1, 126.5, 128.2, 135.2 (aromatic Cs), 137.4 (C-4 of thiazole), 143.2 (methine), 144.5 (C-4 of phenyl), 156.1 (C-8a of chromanone), 178.9 (C-2 of thiazole), 181.0 (C-4 of chromanone). EI-MS  $m/z$  (%): 459.30 (M<sup>+</sup>+2, 8.7%), 458.35 (M<sup>+</sup>+1, 20.16%), 457.35 (M<sup>+</sup>, 20.14%). Anal. Calcd. for C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>5</sub>S<sub>2</sub> (457.52): C, 55.13; H, 4.19; N, 9.18. Found: C, 55.31; H, 4.24; N, 9.34.

#### 4.1.6. 4-(((2-Ethoxy-4-oxochroman-3-ylidene)methyl)amino)-N-(pyridin-2-yl)benzenesulfonamide (**3f**)

Yield: 82%; m.p. 185–187°C. IR (cm<sup>-1</sup>): 3304 (NH), 3030 (aromatic CH), 2927 (aliphatic CH), 1653 (C=O), 1280 (SO<sub>2</sub><sup>asym</sup>), 1159 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (400MHz)  $\delta$ : 1.06 (t, 3H,  $J=7.2$  Hz, CH<sub>2</sub>CH<sub>3</sub>), 3.65 (q, 2H,  $J=7.2$  Hz, CH<sub>2</sub>CH<sub>3</sub>), 5.94 (s, 1H, CH-2, chromone), 7.09–8.05 (m, 13H, ArH), 8.11 (d, 1H,  $J=12.0$  Hz, CH enamine), 11.74 (d, 1H,  $J=12.0$  Hz, NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR  $\delta$ : 14.8(CH<sub>3</sub>), 63.0 (CH<sub>2</sub>), 99.8 (C-2 of chromanone), 113.6 (C-3 of pyridine), 115.7 (C-3+ C-5 of phenyl), 116.7 (C-8 of chromanone), 119.9, 121.2, 122.3, 125.2, 128.5, 129.1, 134.7, 136.3 (aromatic Cs), 139.0 (C-4 of pyridine), 142.9 (methine), 145.6 (C-4 of phenyl), 152.3 (C-6 of pyridine), 155.5 (C-2 of pyridine), 156.3 (C-8a of chromanone), 180.9 (C-4 of chromanone). Anal. Calcd. for C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub>S (451.50): C, 61.19; H, 4.69; N, 9.31. Found: C, 60.09; H, 4.76; N, 9.54.

#### 4.2. General method for the synthesis of compounds (**4a-f**)

A mixture of the appropriate enamine derivatives **3a-f** (10 mmol) and sodium borohydride (3.7 g, 10 mmol) in absolute ethanol (20 mL) was stirred overnight at room temperature. The reaction mixture was diluted with water, neutralized with diluted HCl and the separated solid was filtered off, washed with water and crystallized from ethanol.

##### 4.2.1. 4-(((4-Oxo-4H-chromen-3-yl)methyl)amino)benzenesulfonamide (**4a**)

Yield: 60%; m.p. 242–242°C. IR (cm<sup>-1</sup>): 3304, 3224 (NH, NH<sub>2</sub>), 3118 (aromatic CH), 2920 (aliphatic CH), 1635 (C=O), 1573 (C=C), 1315 (SO<sub>2</sub><sup>asym</sup>), 1147 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz)  $\delta$ : 4.14 (d, 2H,  $J=5.7$  Hz, CH<sub>2</sub>), 6.60 (t, 1H,  $J=6.0$  Hz, NH, exchanged with D<sub>2</sub>O), 6.89 (s, 2H, SO<sub>2</sub>NH<sub>2</sub>, exchanged with D<sub>2</sub>O), 6.68 (d, 1H,  $J=8.7$ , ArH), 7.48 (m, 4H, ArH), 7.62 (d, 1H,  $J=8.7$ , ArH), 7.78 (m, 1H, ArH), 8.08 (d, 1H, ArH), 8.31 (s, 1H, CH-2, chromone). <sup>13</sup>C NMR  $\delta$ : 38.4(CH<sub>2</sub>), 111.6 (C-3+C-5 of phenyl), 118.9 (C-8 of chromone), 121.0, 123.6, 125.4,

125.9, 127.8, 131.0, 134.7 (aromatic Cs), 151.3 (C-4 of phenyl), 154.9 (C-2 of chromone), 156.4 (C-8a of chromone), 176.85 (C-4 of chromone). EI-MS  $m/z$  (%): 331 ( $M^+ + 1$ , 55.1%), 330 ( $M^+$ , 16.33%). Anal. Calcd. for  $C_{16}H_{14}N_2O_4S$  (330.36): C, 58.17; H, 4.27; N, 8.48. Found: C, 58.24; H, 4.31; N, 8.56.

4.2.2. *N*-(5-Methylisoxazol-3-yl)-4-(((4-oxo-4H-chromen-3-yl) methyl) amino)benzenesulfonamide (**4b**)

Yield: 75%; m.p. 204–206 °C. IR ( $cm^{-1}$ ): 3348 (NH), 3070 (aromatic CH), 2974 (aliphatic CH), 1643 (C=O), 1604 (C=C), 1327( $SO_2^{asym}$ ), 1161( $SO_2^{sym}$ ).  $^1H$  NMR (300MHz)  $\delta$ : 2.27 (s, 3H,  $CH_3$ ), 4.12 (d, 2H,  $J = 5.7 Hz$ ,  $CH_2$ ), 6.08 (s, 1H, CH, isoxazole), 6.85 (t, 1H,  $J = 6.0 Hz$ , NH, exchanged with  $D_2O$ ), 6.69-8.07 (m, 8H, ArH), 8.31 (s, 1H, CH-2, chromone), 10.92 (s, 1H,  $SO_2NH$ , exchanged with  $D_2O$ ).  $^{13}C$  NMR  $\delta$ : 11.4 ( $CH_3$ ), 37.2 ( $CH_2$ ), 94.6 (C-4 of isoxazole ring), 110.6 (C-3+C-5 of phenyl), 119.7 (C-8 of chromone), 120.4, 122.6, 124.1, 124.3, 124.8, 124.9, 128.5, 133.6 (aromatic Cs), 151.4 (C-3 of isoxazole), 154.0 (C-2 of chromone ring), 155.3 (C-4 of phenyl), 157.2 (C-8a of chromone), 169.3 (C-5 of isoxazole), 175.7 (C-4 of chromone). EI-MS  $m/z$  (%): 411 ( $M^+$ , 53.0%). Anal. Calcd. for  $C_{20}H_{17}N_3O_5S$  (411.43): C, 58.39; H, 4.16; N, 10.21. Found: C, 58.47; H, 4.20; N, 10.36.

4.2.3. 4-(((4-Oxo-4H-chromen-3-yl)methyl)amino)-*N*-(pyrimidin-2-yl)benzenesulfonamide (**4c**)

Yield: 40%; m.p. 220–222 °C. IR ( $cm^{-1}$ ): 3369 (NH), 3086 (aromatic CH), 2929 (aliphatic CH), 1635 (C=O), 1558 (C=C), 1317 ( $SO_2^{asym}$ ), 1149 ( $SO_2^{sym}$ ).  $^1H$  NMR (400MHz)  $\delta$ : 4.12 (d, 2H,  $J = 5.6 Hz$ ,  $CH_2$ ), 6.78 (t, 1H,  $J = 6.0 Hz$ , NH, exchanged with  $D_2O$ ), 6.59-8.09 (m, 11H, ArH), 8.33 (s, 1H, CH-2, chromone), 11.04 (s, 1H,  $SO_2NH$ , exchanged with  $D_2O$ ).  $^{13}C$ -NMR  $\delta$ : 38.3 ( $CH_2$ ), 111.0 (C-3+ C-5 of phenyl), 114.3 (C-5 of diazine), 117.1 (C-8 of chromone), 118.9, 120.9, 121.5, 123.6, 125.9, 129.6, 134.7 (aromatic Cs), 150.7 (C-2 of chromone), 152.1 (C-4 of phenyl), 155.0 (C-8a of chromone), 157.0 (C-4 + C-6 of diazine), 167.8 (C-2 of diazine), 176.8 (C-4 of chromone). Anal. Calcd. for  $C_{20}H_{16}N_4O_4S$  (408.43): C, 58.82; H, 3.95; N, 13.72. Found: C, 58.97; H, 3.94; N, 13.88.

4.2.4. *N*-(4,6-Dimethylpyrimidin-2-yl)-4-(((4-oxo-4H-chromen-3-yl)methyl)amino)benzenesulfonamide (**4d**)

Yield: 40%; m.p. 165–166 °C. IR ( $cm^{-1}$ ): 3392 (NH), 3080 (aromatic CH), 2926, (aliphatic CH), 1635 (C=O), 1558 (C=C), 1319 ( $SO_2^{asym}$ ), 1149 ( $SO_2^{sym}$ ).  $^1H$  NMR (400MHz)  $\delta$ : 2.23 (s, 6H,  $2CH_3$ ), 4.12 (d, 2H,  $J = 5.6 Hz$ ,  $CH_2$ ), 6.71 (t, 1H,  $J = 6.0 Hz$ , NH, exchanged with  $D_2O$ ), 6.67-8.17 (m, 9 H, ArH), 8.33 (s, 1H, CH-2, chromone), 11.77 (s, 1H,  $SO_2NH$ ,

exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR  $\delta$ : 14.8 (CH<sub>3</sub>), 38.6 (CH<sub>2</sub>), 110.2 (C-5 of pyrimidine), 116.6, 117.9, 120.2, 122.7, 125.4, 126.1, 128.2, 130.3 (aromatic Cs), 150.2 (C-2 of chromone + C-4 of phenyl), 152.2 (C-8a of chromone), 156.6 (C-4 of chromone). Anal. Calcd. for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>4</sub>S (436.49): C, 60.54; H, 4.62; N, 12.84. Found: C, 60.62; H, 4.65; N, 12.97.

#### 4.2.5. 4-(((4-Oxo-4H-chromen-3-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide (**4e**)

Yield: 65%; m.p. 165–166 °C. IR (cm<sup>-1</sup>): 3425 (NH), 3099 (aromatic CH), 2928 (aliphatic CH), 1643 (C=O), 1577 (C=C), 1292 (SO<sub>2</sub><sup>asym</sup>), 1139 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz)  $\delta$ : 4.11 (d, 2H, *J* = 5.7 Hz, CH<sub>2</sub>), 6.72 (t, 1H, NH, *J* = 6.0 Hz, exchanged with D<sub>2</sub>O), 6.65-8.10 (m, 10H, ArH), 8.30 (s, 1H, CH-2, chromone), 12.40 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR  $\delta$ : 37.9 (CH<sub>2</sub>), 107.4(C-3+C-5 of phenyl), 110.8 (C-5 of thiazole), 111.1 (C-8 of chromone), 116.6, 118.4, 120.4, 120.9, 123.1, 124.2, 124.8, 125.4, 134.1 (aromatic Cs), 151.1(C-2 of chromone), 155.9 (C-8a of chromone), 167.9 (C-2 of thiazole), 176.3 (C-4 of chromone). EI-MS *m/z* (%): 413 (M<sup>+</sup>, 8.7). Anal. Calcd. for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> (413.47): C, 55.19; H, 3.66; N, 10.16. Found: C, 55.26; H, 3.72; N, 10.30.

#### 4.2.6. 4-(((4-Oxo-4H-chromen-3-yl)methyl)amino)-N-(pyridin-2-yl)benzenesulfonamide (**4f**)

Yield: 40%; Mp 240–242 °C. IR (cm<sup>-1</sup>): 3352 (NH), 3070 (aromatic CH), 2925 (aliphatic CH), 1643 (C=O), 1465 (C=C), 1276 (SO<sub>2</sub><sup>asym</sup>), 1141 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (400MHz)  $\delta$ : 4.10 (d, 2H, *J* = 5.6 Hz, CH<sub>2</sub>), 6.76 (t, 1H, NH, *J* = 5.6 Hz, exchanged with D<sub>2</sub>O), 6.66-8.09 (m, 12H, ArH), 8.32 (s, 1H, CH-2, chromone), 11.02 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). EI-MS *m/z* (%): 407 (M<sup>+</sup>, 10.0%). Anal. Calcd. for C<sub>21</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>S (407.44): C, 61.91; H, 4.21; N, 10.31. Found: C, 62.03; H, 4.27; N, 10.43.

### 4.3. General method for the synthesis of compounds (**6a-f**)

To a solution of the appropriate *N*-chloroacetyl sulfonamide derivatives **5a-f** (10 mmol) in ethanol (20 mL), ammonium thiocyanate (0.75 g, 10 mmol) was added and the reaction mixture was refluxed for 3-12 h. The reaction mixture was filtered while hot and the obtained solid was crystallized from dioxane to afford the title compounds **6a-f**.

#### 4.3.1. 4-(((4-Oxo-4,5-dihydrothiazol-2-yl)amino)benzenesulfonamide (**6a**)

(Yield: 90%; mp. 244-246 °C; reflux time: 3h. as reported) [50].

#### 4.3.2. N-(5-Methylisoxazol-3-yl)-4-(((4-oxo-4,5-dihydrothiazol-2-yl)amino)benzenesulfonamide (**6b**)

Yield: 85%; m.p. 259–261 °C; reflux time: 8h. IR (cm<sup>-1</sup>): 3334 (NH), 3089 (aromatic CH), 2933 (aliphatic CH), 1689 (C=O), 1244 (SO<sub>2</sub><sup>asym</sup>), 1170 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz) δ: 2.29 (s, 3H, CH<sub>3</sub>), 4.02 (s, 2H, CH<sub>2</sub>), 6.11 (s, 1H, CH, isoxazole), 7.74–7.85 (m, 4H, ArH), 11.35 (s, 1H, NH, exchanged with D<sub>2</sub>O), 11.89 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). EI-MS m/z (%): 352 (M<sup>+</sup>+1.1 %). Anal. Calcd. for C<sub>13</sub>H<sub>12</sub>N<sub>4</sub>O<sub>4</sub>S<sub>2</sub> (352.38): C, 44.31; H, 3.43; N, 15.90. Found: C, 44.39; H, 3.47; N, 16.04.

#### 4.3.3. 4-((4-Oxo-4,5-dihydrothiazol-2-yl)amino)-N-(pyrimidin-2-yl)benzenesulfonamide (**6c**)

Yield: 73%; m.p. 297(dec.); reflux time: 10h. IR (cm<sup>-1</sup>): 3277 (NH), 3039 (aromatic CH), 2941 (aliphatic CH), 1687 (C=O), 1330 (SO<sub>2</sub><sup>asym</sup>), 1161 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (400MHz) δ: 4.03 (s, 2H, CH<sub>2</sub>), 7.03–7.1 (m, 2H, ArH), 7.73–7.97 (m, 3H, ArH), 8.49–8.54 (m, 2H, ArH), 11.79 (br s, 2H, NH and SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). EI-MS m/z (%): 349 (M<sup>+</sup>, 0.5 %). Anal. Calcd. for C<sub>13</sub>H<sub>11</sub>N<sub>5</sub>O<sub>3</sub>S<sub>2</sub> (349.38): C, 44.69; H, 3.17; N, 20.05. Found: C, 44.81; H, 3.20; N, 20.21.

#### 4.3.4. N-(4,6-Dimethylpyrimidin-2-yl)-4-((4-oxo-4,5-dihydrothiazol-2-yl)amino)benzenesulfonamide (**6d**)

Yield: 68%; m.p. 275–277 °C; reflux time: 12h. IR (cm<sup>-1</sup>): 3263 (NH), 3041 (aromatic CH), 2978 (aliphatic CH), 1670 (C=O), 1244(SO<sub>2</sub><sup>asym</sup>), 1143, (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (400MHz) δ: 2.25 (s, 6H, 2 CH<sub>3</sub>), 4.02 (s, 2H, CH<sub>2</sub>), 7.72–7.96 (m, 5H, ArH), 11.76 (br, s, 2H, NH and SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). EI-MS m/z (%): 378 (M<sup>+</sup>+1, 0.6 %), 377 (M<sup>+</sup>, 0.6 %). Anal. Calcd. for C<sub>15</sub>H<sub>15</sub>N<sub>5</sub>O<sub>3</sub>S<sub>2</sub> (377.44): C, 47.73; H, 4.01; N, 18.56. Found: C, 47.88; H, 4.07; N, 18.69.

#### 4.3.5. 4-((4-Oxo-4,5-dihydrothiazol-2-yl)amino)-N-(thiazol-2-yl)benzenesulfonamide (**6e**)

Yield: 88%; m.p. > 300 °C; reflux time: 10h. IR (cm<sup>-1</sup>): 3269 (NH), 3045 (aromatic CH), 2989 (aliphatic CH), 1687 (C=O), 1240 (SO<sub>2</sub><sup>asym</sup>), 1136 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (400MHz) δ: 4.02 (s, 2H, CH<sub>2</sub>), 6.81(d, 1H, J= 4.0 Hz, CH-5, thiazole), 7.25(d, 1H, J= 4.0 Hz, CH-4, thiazole), 7.71–7.90 (m, 4H, ArH), 11.48 (s, 1H, NH exchanged with D<sub>2</sub>O), 12.64 (s, 1H, SO<sub>2</sub>NH exchanged with D<sub>2</sub>O). EI-MS m/z (%): 354 (M<sup>+</sup>, 37.7 %). Anal. Calcd. for C<sub>12</sub>H<sub>10</sub>N<sub>4</sub>O<sub>3</sub>S<sub>3</sub> (354.42): C, 40.67; H, 2.84; N, 15.81. Found: C, 40.75; H, 2.82; N, 15.97.

#### 4.3.6. 4-((4-Oxo-4,5-dihydrothiazol-2-yl)amino)-N-(pyridin-2-yl)benzenesulfonamide (**6f**)

(Yield: 85%; m.p. 240–242 °C; reflux time: 5h as reported) [51].

#### 4.4. General method for the synthesis of compounds (7a-f)

A mixture of chromone-3-carboxaldehyde **2** (1.74 g, 10 mmol), the appropriate thiazolinone derivative **6a-f** (10 mmol) and anhydrous sodium acetate (0.82 g, 10 mmol) in glacial acetic acid (50 mL) was heated in a boiling water bath for 3-12 h. The separated solid was filtered off while hot, washed with hot water and crystallized from DMF/H<sub>2</sub>O.

##### 4.4.1. 4-((4-Oxo-5-((4-oxo-4H-chromen-3-yl)methylene)-4,5-dihydrothiazol-2-yl)amino)benzenesulfonamide (7a)

Yield: 80 %; m.p. > 300 °C; reaction time: 3h. IR (cm<sup>-1</sup>): 3325 (NH), 3290, 3242 (NH<sub>2</sub>), 3049 (aromatic CH), 2950 (aliphatic CH), 1676 (C=O amide), 1643 (C=O, chromone), 1290(SO<sub>2</sub><sup>asym</sup>), 1159 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (400MHz) δ: 7.34 (s, 2H, SO<sub>2</sub>NH<sub>2</sub>, exchanged with D<sub>2</sub>O), 7.44-8.16 (m, 9H, ArH+ methine H), 8.81 (s, 1H, CH-2, chromone), 12.12 (s, 1H, NH exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR δ: 118.9 (C-3 of chromone), 119.0 (C-8 of chromone), 121.3, 122.0, 123.4, 125.2, 125.9, 126.7, 127.0, 127.6, 129.7, 135.5, 138.0 (aromatic Cs), 144.3 (C-9, methine), 154.4 (C-2 of chromone), 155.8 (C-8a of chromone), 160.4 (C-2 of thiazolinone), 166.04 (C-4, C=O of chromone), 175.27 (C-4, C=O of thiazolinone). EI-MS m/z (%): 428 (M<sup>+</sup>+1, 2.3%), 427 (M<sup>+</sup>, 0.5 %). Anal. Calcd. for C<sub>19</sub>H<sub>13</sub>N<sub>3</sub>O<sub>5</sub>S<sub>2</sub> (427.45): C, 53.39; H, 3.07; N, 9.83. Found: C, 53.48; H, 3.12; N, 9.98.

##### 4.4.2. N-(5-Methylisoxazol-3-yl)-4-((4-oxo-5-((4-oxo-4H-chromen-3-yl)methylene)-4,5-dihydrothiazol-2-yl)amino)benzenesulfonamide (7b)

Yield: 85 %; m.p. > 300 °C; reaction time: 8h. IR (cm<sup>-1</sup>): 3263 (NH), 3051(aromatic CH), 2964 (aliphatic CH), 1680 (C=O, amide), 1651 (C=O, chromone), 1238 (SO<sub>2</sub><sup>asym</sup>), 1161 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz) δ: 2.31 (s, 3H, CH<sub>3</sub>), 6.16 (s, 1H, CH, isoxazole), 7.20 (m, 1H, ArH), 7.50-7.70(m, 3H, ArH), 7.82-8.10 (m, 6H, ArH+ methine H+ NH, exchanged with D<sub>2</sub>O), 8.79 (s, 1H, CH-2, chromone), 11.44 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR δ: 11.4 (CH<sub>3</sub>), 94.8 (C-4 of isoxazole), 117.4 (C-8 of chromone), 119.9, 121.4, 122.3, 124.9, 125.7, 127.7, 134.3 (aromatic Cs), 154.7 (C-2 of chromone), 156.4 (C-8a of chromone), 160.0 (C-2 of thiazolinone), 161.7 (C-4 of chromone), 169.7 (C-4 of thiazolinone). EI-MS m/z (%): 509 (M<sup>+</sup>+1, 48%), 508 (M<sup>+</sup>, 48%). Anal. Calcd. for C<sub>23</sub>H<sub>16</sub>N<sub>4</sub>O<sub>6</sub>S<sub>2</sub> (508.52): C, 54.32; H, 3.17; N, 11.02. Found: C, 54.39; H, 3.21; N, 11.13.

##### 4.4.3. 4-((4-Oxo-5-((4-oxo-4H-chromen-3-yl)methylene)-4,5-dihydrothiazol-2-yl)amino)-N-(pyrimidin-2-yl)benzenesulfonamide (7c)

Yield: 78 %; m.p. > 300 °C; reaction time: 12h. IR (cm<sup>-1</sup>): 3250 (NH), 3041 (aromatic CH), 2955 (aliphatic CH), 1680 (C=O, amide), 1649 (C=O, chromone), 1247 (SO<sub>2</sub><sup>asym</sup>), 1157 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz) δ: 7.04-7.18 (m, 2H, ArH), 7.53-7.71(m, 3H, ArH), 7.83-8.11(m, 5H, ArH), 8.51-8.53(m, 2H, ArH, +methine H), 8.79 (s, 1H, CH-2, chromone), 11.85 (s, 2H, NH and SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR δ: 116.2 (C-8 of chromone), 118.5, 119.0, 120.5, 121.9, 123.0, 123.3, 126.0, 126.7, 129.6, 135.4 (aromatic Cs), 155.8 (C-8a of chromone), 157.3 (C-2 of thiazolinone + C-4 and C-6 of diazine), 158.8 (C-4 of thiazolinone + C-2 of diazine), 160.9 (C-4 of chromone). EI-MS m/z (%): 505 (M<sup>+</sup>, 5%). Anal. Calcd. for C<sub>23</sub>H<sub>15</sub>N<sub>5</sub>O<sub>5</sub>S<sub>2</sub> (505.52): C, 54.65; H, 2.99; N, 13.85. Found: C, 54.72; H, 3.02; N, 14.03.

4.4.4. *N*-(4,6-Dimethylpyrimidin-2-yl)-4-((4-oxo-5-((4-oxo-4H-chromen-3-yl)methylene)-4,5-dihydrothiazol-2-yl)amino)benzene sulfonamide (**7d**)

Yield: 69%; m.p. > 300 °C; reaction time: 12h. IR (cm<sup>-1</sup>): 3313 (NH), 3043 (aromatic CH), 2957 (aliphatic CH), 1680 (C=O, amide), 1647 (C=O, chromone), 1246 (SO<sub>2</sub><sup>asym</sup>), 1163 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (400MHz) δ: 2.27 (s, 6H, 2CH<sub>3</sub>), 6.76 (s, 1H, CH-5, pyrimidine), 7.45-7.56 (m, 3H, ArH+ methine H), 7.69-7.85 (m, 3H, ArH), 7.94-8.12 (m, 3H, ArH), 8.69 (s, 1H, CH-2, chromone), 11.89 (s, 2H, NH and SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR δ: 22.7 (CH<sub>3</sub>), 113.2 (C-5 of pyrimidine), 118.4 (C-3+C-5 of phenyl), 121.0 (C-8 of chromone), 122.3, 122.9, 125.1, 126.0, 126.4, 127.1, 128.2, 128.9, 130.4, 131.2, 134.8 (aromatic Cs), 155.2 (C-2 of chromone), 156.0 (C-8a of chromone), 160.3 (C-2 of thiazolinone), 169.6 (C-4+C-6 of pyrimidine), 185.7 (C-4 of thiazolinone), 193.2 (C-4 of chromone). EI-MS m/z (%): 533 (M<sup>+</sup>, 12.0%). Anal. Calcd. for C<sub>25</sub>H<sub>19</sub>N<sub>5</sub>O<sub>5</sub>S<sub>2</sub> (533.58): C, 56.28; H, 3.59; N, 13.13. Found: C, 56.39; H, 3.64; N, 13.28.

4.4.5. 4-((4-Oxo-5-((4-oxo-4H-chromen-3-yl)methylene)-4,5-dihydrothiazol-2-yl)amino)-*N*-(thiazol-2-yl)benzenesulfonamide (**7e**)

Yield: 65%; m.p. > 300 °C; reaction time: 8h. IR (cm<sup>-1</sup>): 3246 (NH), 3043 (aromatic CH), 2950 (aliphatic CH), 1674 (C=O, amide), 1651 (C=O chromone), 1321 (SO<sub>2</sub><sup>asym</sup>), 1184 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz) δ: 6.84 (d, 1H, *J*= 4.0 Hz, CH-5, thiazole), 7.14-7.15(m, 1H, ArH), 7.27 (d, 1H, *J*= 4.0 Hz, CH-4, thiazole), 7.50-7.92(m, 7H, ArH), 8.08(s, 1H, methine H), 8.79 (s, 1H, CH-2, chromone), 12.40, 12.75 (s, 2H, NH and SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR δ: 108.7 (C-5 of thiazole + C-3 and C-5 of phenyl), 118.5 (C-8 of chromone), 119.0, 120.7, 122.0, 122.8, 123.4, 124.9, 126.0, 126.7, 127.7, 135.4, 138.7 (aromatic Cs), 155.8 (C-8a of chromone), 160.9 (C-4 of thiazolinone), 169.2 (C-4 of chromone). EI-MS m/z (%): 510 (M<sup>+</sup>,

2.8%). Anal. Calcd. for  $C_{22}H_{14}N_4O_5S_3$  (510.56): C, 51.76; H, 2.76; N, 10.97. Found: C, 51.79; H, 2.78; N, 11.13.

4.4.6. 4-((4-Oxo-5-((4-oxo-4H-chromen-3-yl)methylene)-4,5-dihydrothiazol-2-yl)amino)-N-(pyridin-2-yl)benzenesulfonamide (**7f**)

Yield: 70%; m.p. > 300 °C; reaction time: 4h. IR ( $cm^{-1}$ ): 3244 (NH), 3022 (aromatic CH), 2945 (aliphatic CH), 1681 (C=O, amide), 1649 (C=O chromone), 1280 ( $SO_2^{asym}$ ), 1178 ( $SO_2^{sym}$ ).  $^1H$  NMR (300MHz)  $\delta$ : 6.80-6.90 (m, 1H, ArH), 7.17-7.20 (m, 2H, ArH), 7.47-7.52 (m, 2H, ArH), 7.66-7.87 (m, 6H, ArH), 8.02-8.04 (m, 2H, ArH+methine H), 8.71 (s, 1H, CH-2, chromone), 12.00 (s, 2H, NH and  $SO_2NH$ , exchanged with  $D_2O$ ).  $^{13}C$  NMR  $\delta$ : 102.1 (C-3 of pyridine), 113.7 (C-3+C-5 of phenyl), 115.5 (C-8 of chromone), 118.4, 118.7, 120.5, 121.3, 122.8, 125.4, 126.1, 126.8, 127.5, 128.3, 129.4, 130.5, 134.7 (aromatic Cs), 140.2 (C-6 of pyridine), 147.4 (C-2 of chromone), 153.0 (C-8a of chromone), 155.3 (C-4 of thiazolinone), 170.0 (C-4 of chromone). Anal. Calcd. for  $C_{24}H_{16}N_4O_5S_2$  (504.54): C, 57.13; H, 3.20; N, 11.10. Found: C, 57.27; H, 3.18; N, 11.27.

4.5. General method for the synthesis of compounds (**10a-f**) and (**11a-f**).

An equimolar mixture of the oxazolone **9a** or **9b** and the appropriate sulfonamide derivative (10 mmol) and anhydrous sodium acetate (0.03 g, 0.36 mmol) in glacial acetic acid (20 mL) was heated in a boiling water bath while stirring for 8-24 h. The separated solid was filtered off while hot, washed with water, and crystallized from DMF/ $H_2O$ .

4.5.1. 4-(5-Oxo-4-((4-oxo-4H-chromen-3-yl)methylene)-2-phenyl-4,5-dihydro-1H-imidazol-1-yl)benzenesulfonamide (**10a**)

Yield: 82%; m.p. 292-294 °C; reaction time: 8h. IR ( $cm^{-1}$ ): 3311, 3265 ( $NH_2$ ), 3050 (aromatic CH), 2950 (aliphatic CH), 1683 (C=O, imidazolinone), 1653 (C=O, chromone), 1593 (C=C), 1315 ( $SO_2^{asym}$ ), 1159 ( $SO_2^{sym}$ ).  $^1H$  NMR (300MHz)  $\delta$ : 6.79-7.10 (m, 2H, ArH), 7.23 (s, 2H,  $SO_2NH_2$ , exchanged with  $D_2O$ ), 7.52-7.99 (m, 12H, ArH), 8.72 (s, 1H, CH-2 of chromone).  $^{13}C$  NMR  $\delta$ : 119.9 (C-8 of chromone), 123.6, 126.0, 126.5, 126.9, 128.2, 128.9, 132.4, 133.6, 139.0 (aromatic Cs), 142.6 (C-2 of chromone), 155.8 (C-8a of chromone), 158.5 (C-2 of imidazolinone), 164.6 (C-4 of imidazolinone), 175.9 (C-4 of chromone). EI-MS m/z (%): 472 ( $M^+ + 1$ , 4.6%). Anal. Calcd. for  $C_{25}H_{17}N_3O_5S$  (471.49): C, 63.69; H, 3.63; N, 8.91. Found: C, 63.81; H, 3.65; N, 8.99.

4.5.2. N-(5-Methylisoxazol-3-yl)-4-(5-oxo-4-((4-oxo-4H-chromen-3-yl)methylene)-2-phenyl-4,5-dihydro-1H-imidazol-1-yl)benzenesulfonamide (**10b**)

Yield: 75%; m.p. 295-296 °C; reaction time: 8h. IR (cm<sup>-1</sup>): 3251 (NH), 3010 (aromatic CH), 2926 (aliphatic CH), 1687 (C=O, imidazolinone), 1656 (C=O, chromone), 1591 (C=C), 1317 (SO<sub>2</sub><sup>asym</sup>), 1166 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz) δ: 2.30 (s, 3H, CH<sub>3</sub>), 6.12 (s, 1H, CH, isoxazole), 6.76 (s, 1H, methine H), 7.51- 8.19 (m, 13H, ArH), 8.73 (s, 1H, CH-2 of chromone), 10.60 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR δ: 12.0 (CH<sub>3</sub>), 95.3 (C-4 of isoxazole), 115.4 (C-8 of chromone), 119.6, 123.1, 125.4, 126.0, 127.7, 127.8, 128.4, 131.9, 133.1, 133.1, 133.2, 134.6 (aromatic Cs), 149.5 (C-1 of phenyl sulfonamide), 155.3 (C-2 of chromone), 157.5 (C-3 of isoxazole), 157.5 (C-8a of chromone), 158.1 (C-2 of imidazolinone), 164.3 (C-5 of isoxazole), 170.2 (C-4 of imidazolinone), 175.4 (C-4 of chromone). EI-MS m/z (%): 552 (M<sup>+</sup>, 40.7 %). Anal. Calcd. for C<sub>29</sub>H<sub>20</sub>N<sub>4</sub>O<sub>6</sub>S (552.56): C, 63.04; H, 3.65; N, 10.14. Found: C, 63.08; H, 3.64; N, 10.22.

4.5.3. 4-(5-Oxo-4-((4-oxo-4H-chromen-3-yl)methylene)-2-phenyl-4,5-dihydro-1H-imidazol-1-yl)-N-(pyrimidin-2-yl)benzenesulfonamide (**10c**)

Yield: 60%; m.p. 280-282 °C; reaction time: 10h. IR (cm<sup>-1</sup>): 3421 (NH), 3034 (aromatic CH), 2932 (aliphatic CH), 1680 (C=O, imidazolinone), 1653 (C=O, chromone), 1593 (C=C), 1319(SO<sub>2</sub><sup>asym</sup>), 1165 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz) δ: 6.75 (s, 1H, methine H), 7.03 (m, 1H, ArH), 7.48-7.53 (m, 12H, ArH), 8.16-8.17(m, 1H, ArH), 8.49-8.51 (m, 2H, ArH), 8.72 (s, 1H, CH-2 of chromone), 10.55 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR δ: 115.4 (C-5 of pyrimidine), 118.4 (C-8 of chromone), 118.8, 119.1, 120.2, 122.2, 122.9, 123.8, 125.7, 127.1, 128.6, 129.5, 130.4, 132.7, 133.1, 134.6 (aromatic Cs), 143.1 (C-2 of chromone), 155.2 (C-8a of chromone), 158.1 (C-4 + C-6 of pyrimidine + C-2 of imidazolinone), 164.2 (C-2 of pyrimidine), 164.9 (C-4 of imidazolinone), 175.4 (C-4 of chromone). Anal. Calcd. for C<sub>29</sub>H<sub>19</sub>N<sub>5</sub>O<sub>5</sub>S (559.56): C, 63.38; H, 3.48; N, 12.74. Found: C, 63.52; H, 3.46; N, 12.91.

4.5.4. N-(4,6-Dimethylpyrimidin-2-yl)-4-(5-oxo-4-((4-oxo-4H-chromen-3-yl)methylene)-2-phenyl-4,5-dihydro-1H-imidazol-1-yl)benzenesulfonamide (**10d**)

Yield: 45%; m.p. 212-213 °C; reaction time: 12h. IR (cm<sup>-1</sup>): 3242 (NH), 3062 (aromatic CH), 2926 (aliphatic CH), 1718 (C=O, imidazolinone), 1651 (C=O, chromone), 1595 (C=C), 1313(SO<sub>2</sub><sup>asym</sup>), 1159(SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz) δ: 2.24 (s, 6H, 2CH<sub>3</sub>), 6.75 (s, 1H, methine H), 7.41- 8.01 (m, 14 H, ArH), 8.70 (s, 1H, CH-2 of chromone), 10.60 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). EI-MS m/z (%): 577 (M<sup>+</sup>, 8.0 %). Anal. Calcd. for C<sub>31</sub>H<sub>23</sub>N<sub>5</sub>O<sub>5</sub>S (577.62): C, 64.46; H, 4.01; N, 12.12; S, 5.55. Found: C, 64.59; H, 4.09; N, 12.21; S, 5.62.

4.5.5. 4-(5-Oxo-4-((4-oxo-4H-chromen-3-yl)methylene)-2-phenyl-4,5-dihydro-1H-imidazol-1-yl)-N-(thiazol-2-yl)benzenesulfonamide (**10e**)

Yield: 80%; m.p. 241-246 °C; reaction time: 8h. IR (cm<sup>-1</sup>): 3379 (NH), 3032(aromatic CH), 2925 (aliphatic CH), 1672 (C=O, imidazolinone), 1649 (C=O, chromone), 1587 (C=C), 1317(SO<sub>2</sub><sup>asym</sup>), 1143 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (400MHz) δ: 6.77 (s, 1H, methine H), 6.81 (d, 1H, CH-5, *J*= 4.0 Hz, thiazole), 7.24 (d, 1H, CH-4, *J*= 4.0 Hz, thiazole), 7.52- 7.61 (m, 4H, ArH), 7.71-7.78 (m, 3H, ArH), 7.85-7.89 (m, 3H, ArH), 7.97-7.99 (m, 2H, ArH), 8.17-8.19 (m, 1H, ArH), 8.73 (s, 1H, CH-2 of chromone), 10.53 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR δ: 108.3 (C-5 of thiazole), 115.8 (C-8 of chromone), 118.7, 119.1, 119.7, 123.4, 125.8, 126.3, 127.0, 128.0, 128.7, 132.2, 133.5, 135.0, 136.8 (aromatic Cs), 142.7 (C-4 of thiazole + C-4 of phenyl), 148.4 (C-2 of chromone), 155.6 (C-8a of chromone), 158.3 (C-2 of imidazolinone), 164.4 (C-4 of imidazolinone), 171.3 (C-2 of thiazole), 175.8 (C-4 of chromone). EI-MS *m/z* (%): 554 (M<sup>+</sup>, 1.1%). Anal. Calcd. for C<sub>28</sub>H<sub>18</sub>N<sub>4</sub>O<sub>5</sub>S<sub>2</sub> (554.60): C, 60.64; H, 3.27; N, 10.10. Found: C, 60.68; H, 3.29; N, 11.13.

4.5.6. 4-(5-Oxo-4-((4-oxo-4H-chromen-3-yl)methylene)-2-phenyl-4,5-dihydro-1H-imidazol-1-yl)-N-(pyridin-2-yl)benzenesulfonamide (**10f**)

Yield: 70%; m.p. 246-248 °C; reaction time: 8h. IR (cm<sup>-1</sup>): 3261 (NH), 3051 (aromatic CH), 2931 (aliphatic CH), 1685 (C=O, imidazolinone), 1655 (C=O, chromone), 1591 (C=C), 1319(SO<sub>2</sub><sup>asym</sup>), 1163 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz) δ: 6.75 (s, 1H, methine H), 7.15-7.98 (m, 17 H, ArH), 8.71 (s, 1H, CH-2 of chromone), 10.50 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR δ: 115.9 (C-3 of pyridine), 119.9 (C-8 of chromone), 123.6, 126.0, 126.5, 128.1, 128.3, 128.9, 132.4, 133.6, 135.2 (aromatic Cs), 143.0 (C-6 of pyridine), 155.8 (C-2 of chromone), 158.5 (C-8a of chromone), 164.6 (C-2 of imidazolinone), 165.5 (C-4 of imidazolinone), 175.9 (C-4 of chromone). EI-MS *m/z* (%): 548 (M<sup>+</sup>, 65.3%). Anal. Calcd. for C<sub>30</sub>H<sub>20</sub>N<sub>4</sub>O<sub>5</sub>S (548.57): C, 65.68; H, 3.67; N, 10.21. Found: C, 65.76; H, 3.64; N, 10.40.

4.5.7. 4-(2-(4-Chlorophenyl)-5-oxo-4-((4-oxo-4H-chromen-3-yl)methylene)-4,5-dihydro-1H-imidazol-1-yl)benzenesulfonamide (**11a**)

Yield: 62%; m.p. > 300 °C; reaction time: 18h. IR (cm<sup>-1</sup>): 3338, 3288 (NH<sub>2</sub>), 3059 (aromatic CH), 2930 (aliphatic CH), 1681 (C=O, imidazolinone), 1656 (C=O, chromone), 1595 (C=C), 1300 (SO<sub>2</sub><sup>asym</sup>), 1161 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz) δ: 6.83 (s, 1H, methine H), 7.24 (s, 2H, SO<sub>2</sub>NH<sub>2</sub>, exchanged with D<sub>2</sub>O), 7.55-7.97 (m, 11H, ArH), 8.15-8.19 (m, 1H, ArH), 8.72 (s, 1H, CH-2, chromone). <sup>13</sup>C NMR δ: 115.8 (C-8 of chromone), 119.6, 123.1, 125.4, 126.0, 127.8,

128.5, 129.6, 132.0, 132.8, 133.3, 134.6, 136.6 (aromatic Cs), 143.4 (C-2 of chromone), 157.5 (C-8a of chromone), 158.1 (C-2 of imidazolinone), 164.1 (C-4 of imidazolinone), 175.8 (C-4 of chromone). EI-MS  $m/z$  (%): 507.02 ( $M^+ + 2$ , 0.7%), 505.03 ( $M^+$ , 2.0%). Anal. Calcd. for  $C_{25}H_{16}ClN_3O_5S$  (505.93): C, 59.35; H, 3.19; N, 8.31. Found: C, 59.42; H, 3.21; N, 8.44.

4.5.8. 4-(2-(4-Chlorophenyl)-5-oxo-4-((4-oxo-4H-chromen-3-yl) methylene)-4,5-dihydro-1H-imidazol-1-yl)-N-(5-methylisoxazol-3-yl)benzenesulfonamide (**11b**)

Yield: 75%; m.p. 295-297 °C; reaction time: 12h. IR ( $cm^{-1}$ ): 3250 (NH), 3161 (aromatic CH), 2924 (aliphatic CH), 1687 (C=O, imidazolinone), 1654 (C=O, chromone), 1591 (C=C), 1317( $SO_2^{asym}$ ), 1165 ( $SO_2^{sym}$ ).  $^1H$  NMR (300MHz)  $\delta$ : 2.29 (s, 3H,  $CH_3$ ), 6.10 (s, 1H, CH, isoxazole), 6.79 (s, 1H, methine H), 7.55-7.99 (m, 11H, ArH), 8.17-8.18 (m, 1H, ArH), 8.73 (s, 1H, CH-2 chromone), 10.57 (s, 1H,  $SO_2NH$ , exchanged with  $D_2O$ ).  $^{13}C$  NMR  $\delta$ : 12.0 ( $CH_3$ ), 95.3 (C-4 of isoxazole), 115.9 (C-8 of chromone), 119.6, 123.1, 125.4, 126.0, 127.8, 128.5, 129.6, 132.0, 132.8, 133.3, 134.6, 136.8 (aromatic Cs), 155.3 (C-2 of chromone), 157.5 (C-3 of isoxazole), 158.1 (C-8a of chromone + C-2 of imidazolinone), 164.1 (C-5 of isoxazole), 170.2 (C-4 of imidazolinone), 175.3 (C-4 of chromone). EI-MS  $m/z$  (%): 588.01 ( $M^+ + 2$ , 2.2%), 586 ( $M^+$ , 6.9%). Anal. Calcd. for  $C_{29}H_{19}ClN_4O_6S$  (586.07): C, 59.34; H, 3.26; N, 9.54. Found: C, 59.42; H, 3.29; N, 9.68.

4.5.9. 4-(2-(4-Chlorophenyl)-5-oxo-4-((4-oxo-4H-chromen-3-yl) methylene)-4,5-dihydro-1H-imidazol-1-yl)-N-(pyrimidin-2-yl)benzenesulfonamide (**11c**)

Yield: 40%; m.p. 284-288 °C; reaction time: 14h. IR ( $cm^{-1}$ ): 3284 (NH), 3041 (aromatic CH), 2950 (aliphatic CH), 1683 (C=O, imidazolinone), 1656 (C=O, chromone), 1591 (C=C), 1315( $SO_2^{asym}$ ), 1163 ( $SO_2^{sym}$ ).  $^1H$  NMR (300MHz)  $\delta$ : 6.79 (s, 1H, methine H), 7.01-7.04 (m, 2H, ArH), 7.52-7.99 (m, 8H, ArH), 8.15-8.18 (m, 2H, ArH), 8.49-8.51 (m, 3H, ArH), 8.73 (s, 1H, CH-2, chromone), 10.54 (s, 1H,  $SO_2NH$ , exchanged with  $D_2O$ ).  $^{13}C$  NMR  $\delta$ : 115.9 (C-5 of pyrimidine), 118.4 (C-8 of chromone), 118.7 (C-3 of chromone), 119.2, 123.1, 125.4, 126.0, 128.5, 128.6, 129.6, 132.0, 132.8, 134.3, 134.6, 136.7 (aromatic Cs), 143.0 (C-1 of phenyl), 155.3 (C-2 of chromone), 156.9 (C-8a of chromone), 158.0 (C-4 + C-6 of pyrimidine + C-2 of imidazolinone), 158.2 (C-2 of pyrimidine), 164.0 (C-4 of imidazolinone), 175.3 (C-4 of chromone). Anal. Calcd. for  $C_{29}H_{18}ClN_5O_5S$  (583.07): C, 59.64; H, 3.11; N, 11.99. Found: C, 59.73; H, 3.14; N, 12.13.

4.5.10. 4-(2-(4-Chlorophenyl)-5-oxo-4-((4-oxo-4H-chromen-3-yl) methylene)-4,5-dihydro-1H-imidazol-1-yl)-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide (**11d**)

Yield: 43%; m.p. 261-268 °C; reaction time: 24h. IR (cm<sup>-1</sup>): 3363 (NH), 3089 (aromatic CH), 2927 (aliphatic CH), 1697 (C=O, imidazolinone), 1653 (C=O, chromone), 1591 (C=C), 1315(SO<sub>2</sub><sup>asym</sup>), 1149 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (400MHz) δ: 2.26 (s, 6H, 2CH<sub>3</sub>), 6.76 (s, 1H, ArH, pyrimidine), 6.80 (s, 1H, methine H), 7.54-7.58 (m, 3H, ArH), 7.61-7.63 (m, 1H, ArH), 7.71-7.73 (m, 3H, ArH), 7.95-7.99 (m, 4H, ArH), 8.15-8.17 (m, 1H, ArH), 8.73 (s, 1H, CH-2 chromone), 10.54 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR δ: 23.3 (CH<sub>3</sub>), 114.0 (C-5 of pyrimidine), 118.9 (C-8 of chromone), 119.2, 119.3, 123.6, 125.9, 126.5, 129.0, 129.5, 130.2, 132.5, 133.3, 135.1, 137.3 (aromatic Cs), 143.3 (C-2 of chromone), 155.8 (C-8a of chromone), 156.7 (C-2 of imidazolinone), 158.5 (C-4 + C-6 of pyrimidine), 164.5 (C-2 of pyrimidine), 164.6 (C-4 of imidazolinone), 175.8 (C-4 of chromone). Anal. Calcd. for C<sub>31</sub>H<sub>22</sub>ClN<sub>5</sub>O<sub>5</sub>S (611.06): C, 60.83; H, 3.62; N 11.44; S, 5.24. Found: C, 60.90; H, 3.69; N, 11.58; S, 5.33.

*4.5.11. 4-(2-(4-Chlorophenyl)-5-oxo-4-((4-oxo-4H-chromen-3-yl) methylene)-4,5-dihydro-1H-imidazol-1-yl)-N-(thiazol-2-yl)benzenesulfonamide (11e)*

Yield: 72%; m.p. 268-271 °C; reaction time: 24h. IR (cm<sup>-1</sup>): 3300 (NH), 3084 (aromatic CH), 2935 (aliphatic CH), 1672 (C=O, imidazolinone), 1651 (C=O, chromone), 1587 (C=C), 1313(SO<sub>2</sub><sup>asym</sup>), 1143 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (400MHz) δ: 6.80 (s, 1H, methine H), 6.81 (d, 1H, CH-5, *J* = 4.0 Hz, thiazole), 7.43 (d, 1H, CH-4, *J* = 4.0 Hz, thiazole), 7.46-7.99 (m, 11H, ArH), 8.15-8.17 (m, 1H, ArH), 8.73 (s, 1H, CH-2, chromone), 10.52 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). <sup>13</sup>C NMR δ: 108.5 (C-5 of thiazole), 116.5 (C-8 of chromone), 119.9, 123.6, 124.8, 125.9, 126.5, 127.2, 127.4, 128.6, 129.0, 130.1, 131.4, 132.5, 133.3, 135.1, 137.0, 137.2 (aromatic Cs), 138.4 (C-4 of thiazole), 142.8 (C-2 of chromone), 155.8 (C-8a of chromone), 158.5 (C-2 of imidazolinone), 164.5 (C-4 of imidazolinone), 168.7 (C-2 of thiazole), 175.8 (C-4 of chromone). EI-MS *m/z* (%): 590 (M<sup>+</sup>+2, 7.5%), 588.01 (M<sup>+</sup>, 22.8%). Anal. Calcd. for C<sub>28</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>5</sub>S<sub>2</sub> (589.04): C, 57.09; H, 2.91; N, 9.51. Found: C, 57.20; H, 2.97; N, 9.62

*4.5.12. 4-(2-(4-Chlorophenyl)-5-oxo-4-((4-oxo-4H-chromen-3-yl) methylene)-4,5-dihydro-1H-imidazol-1-yl)-N-(pyridin-2-yl)benzene sulfonamide (11f)*

Yield: 45%; m.p. 285-287 °C; reaction time: 15h. IR (cm<sup>-1</sup>): 3269 (NH), 3059 (aromatic CH), 2926 (aliphatic CH), 1683 (C=O, imidazolinone), 1653 (C=O, chromone), 1593 (C=C), 1313(SO<sub>2</sub><sup>asym</sup>), 1166 (SO<sub>2</sub><sup>sym</sup>). <sup>1</sup>H NMR (300MHz) δ: 6.79 (s, 1H, methine H), 7.03-7.04 (m, 1H, ArH), 7.55-7.99 (m, 14H, ArH), 8.15-8.17 (m, 1H, ArH), 8.73 (s, 1H, CH-2, chromone), 10.54 (s, 1H, SO<sub>2</sub>NH, exchanged with D<sub>2</sub>O). EI-MS *m/z* (%): 584 (M<sup>+</sup>+2, 3.5%), 582 (M<sup>+</sup>,

10.7%) . Anal. Calcd. for  $C_{30}H_{19}ClN_4O_5S$  (583.01): C, 61.80; H, 3.28, N; 9.61; S, 5.50 . Found: C, 61.92; H, 3.24; N,9.73; S, 5.61.

#### 4.2. *In vitro* cytotoxic activity:

##### 4.2.1. Cell culture:

MCF-7 human breast cancer cells, grown in RPMI-1640 medium; and A-549 human lung cancer cells, grown in DMEM, were supplemented with 10% heat inactivated FBS, 50 units/mL of penicillin and 50 mg/mL of streptomycin and were maintained at 37° C in a humidified atmosphere containing 5% CO<sub>2</sub>. The cells were maintained as “monolayer culture” by serial subculturing.

##### 4.2.2. Sulforhodamine B assay (SRB):

Exponentially growing cells were collected using 0.25% Trypsin-EDTA and seeded in 96-well plates at 1000-2000 cells/well in RPMI supplemented medium or in DMEM supplemented medium. After 24 h, the cells were incubated for 72 h with various concentrations of the tested compounds. Following 72 h treatment, the cells were fixed with 10% trichloroacetic acid for 1 h at 4 °C. Wells were stained for 10 min at room temperature with 0.4% SRB dissolved in 1% acetic acid. The plates were air dried for 24 h and the dye was solubilized with Tris-HCl for 5 min on a shaker at 1600 rpm. The optical density (OD) of each well was measured spectrophotometrically at 564 nm with an ELISA microplate reader (ChroMate-4300, FL, USA). The IC<sub>50</sub> values were calculated according to the equation for Boltzman sigmoidal concentration–response curve using the nonlinear regression fitting models (Graph Pad, Prism Version 5).

##### 4.3. Carbonic anhydrase inhibition:

An Applied Photophysics stopped-flow instrument was used for assaying the CA catalysed CO<sub>2</sub> hydration activity [49]. Phenol red (at a concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.5) as buffer, and 20 mM Na<sub>2</sub>SO<sub>4</sub> (for maintaining constant the ionic strength), following the initial rates of the CA-catalyzed CO<sub>2</sub> hydration reaction for a period of 10-100 s. The CO<sub>2</sub> concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor at least six traces of the initial 5-10% of the reaction was used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitor (0.1

mM) were prepared in distilled-deionized water and dilutions up to 0.01 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. The inhibition constants were obtained by non-linear least-squares methods using the Cheng-Prusoff equation, as reported earlier [52-54], and represent the mean from at least three different determinations. All four CA isoforms were recombinant ones obtained in-house as reported earlier [51-53].

#### 4.4. Apoptosis study:

MCF-7 or A-549 cells ( $1 \times 10^5$  cells/ml) were plated in a 24-well culture plate (Corning) for 24 h at 37 °C with 5% CO<sub>2</sub> and 95% humidity. The tested compound **4a** was added. Cells were incubated for another 24 h. Cells were trypsinized with 0.25% trypsin in Ca<sup>2+</sup>/Mg<sup>2+</sup>-free 2% BSA-PBS (Sigma, St. Louis, MO, USA) and washed twice with Ca<sup>2+</sup>/Mg<sup>2+</sup>-free PBS. Cells were stained and adjusted to  $1 \times 10^6$  cells/ml with annexin V-FITC/PI. The reaction was allowed to proceed in the dark for 30 min at room temperature. Finally, 400 µl of 1 x binding buffer was added and flow cytometry carried out within 1 h.

#### References.

1. H. M. el-Shaar, P. Foltinova, M. Lacova, J. Chovancova, H. Stankovicova, *Farmaco* 53 (1998) 224-232.
2. Z. H. Chohan, A. Rauf, M. M. Naseer, M. A. Somra, C. T. Supuran, *J. Enzyme Inhib. Med. Chem.* 21 (2006) 173-177.
3. D. H. Nam, K. Y. Lee, C. S. Moon, Y. S. Lee, *Eur. J. Med. Chem.* 45 (2010) 4288-4292.
4. W. Huang, Y. Ding, Y. Miao, M. Z. Liu, Y. Li, G. F. Yang, *Eur. J. Med. Chem.* 44 (2009) 3687-3696.
5. N. Desideri, P. Mastromarino, C. Conti, *Antivir. Chem. Chemother.* 14 (2003) 195-203.
6. P. J. Houghton, T. Z. Woldemariam, A. I. Khan, A. Burke, N. Mahmood, *Antiviral Res.* 25 (1994) 235-244.

7. G. C. Kaspentakis, C. A. Tsoleridis, J. S. Stephanatou, *J. Heterocycl. Chem.* 44 (2007) 425-430.
8. V. Sosnovskikh, V. Moshkin, *Russ. Chem. Bull.* 59 (2010) 1056-1058.
9. A. Nohara, T. Umetani, Y. Sanno, *Tetrahedron* 30 (1974) 3553-3561.
10. A. Nohara, T. Umetani, Y. Sanno, *Tetrahedron Lett.* 22 (1973) 1995-1998.
11. E. L. R. Stokstad, T. H. Jukes, *J. Nutr.* 117 (1987) 1335-1341.
12. Y. L. Hong, P. A. Hossler, D. H. Calhoun, S. R. Meshnic, *Antimicrob. Agents Chemother.* 39 (1995) 1756-1763.
13. M. N. L. Nalam, A. Peeters, T. H. M. Jonckers, I. Dierynck, C. A. Schiffer, *J. Virol.* 81 (2007) 9512-9518.
14. S. K. Suthar, S. Bansal, S. Lohan, V. Modak, A. Chaudhary, A. Tiwari, *Eur. J. Med. Chem.* 66 (2013) 372-379.
15. S. M. Monti, C. T. Supuran, G. De Simone, *Expert Opin. Ther. Pat.* 23 (2013) 737-749.
16. V. Alterio, A. Di Fiore, K. D'Ambrosio, C.T. Supuran, G. De Simone, *Chem. Rev.* 112 (2012) 4421-4468.
17. I. Nishimori, T. Minakuchi, T. Kohsaki, S. Onishi, H. Takeuchi, D. Vullo, A. Scozzafava, C. T. Supuran, *Bioorg. Med. Chem. Lett.* 17 (2007) 3585-3594.
18. C.T. Supuran, *J. Enzyme Inhib. Med. Chem.* 27 (2012) 759-772.
19. M. Zareef, R. Iqbal, N. G. De Dominguez, J. Rodrigues, J. H. Zaidi, M. Arfan, C. T. Supuran, *J. Enzyme Inhib. Med. Chem.* 22 (2007) 301-308.
20. C.T. Supuran, *J. Enzyme Inhib. Med. Chem.* 28 (2013) 229-230.
21. C.T. Supuran, *Bioorg. Med. Chem. Lett.* 20 (2010) 3467-3474.
22. C.T. Supuran, *Nat. Rev. Drug. Discov.* 7 (2008) 168-181.

23. C.T. Supuran, R. McKenna, Carbonic anhydrase inhibitors drug design, in *Carbonic Anhydrase: Mechanism, regulation, Links to Disease, and Industrial Applications*, McKenna R, Frost S, Eds., Springer Verlag, Heidelberg, 2014, pp. 291-323.
24. A.J. Esbaugh, B.L. Tufts, *Respir. Physiol. Neurobiol.* 154 (2006) 185-198.
25. I. Nishimori, T. Minakuchi, S. Onishi, D. Vullo, A. Cecchi, A. Scozzafava, C.T. Supuran, *Bioorg. Med. Chem.* 15 (2007) 7229-7236.
26. D. Neri, C.T. Supuran, *Nat. Rev. Drug Disc* 10 (2011) 767-777.
27. C.T. Supuran, A. Scozzafava, *Bioorg. Med. Chem.* 15 (2007) 4336-4350.
28. F. Pacchiano, F. Carta, P.C. McDonald, Y. Lou, D. Vullo, A. Scozzafava, S. Dedhar, C.T. Supuran, *J. Med. Chem.* 54 (2011) 1896-1902.
29. L. Puccetti, G. Fasolis, D. Vullo, Z. H. Chohan, A. Scozzafava, C. T. Supuran, *Bioorg Med. Chem. Lett.* 15 (2005) 3096-3101.
30. P.-C. Lv, C.-F. Zhou, J. Chen, P.-G. Liu, K.-R. Wang, W.-J. Mao, H.-Q. Li, Y. Yang, J. Xiong, H.-L. Zhu, *Bioorg. Med. Chem.* 18 (2010) 314-319.
31. D. Havrylyuk, L. Mosula, B. Zimenkovsky, O. Vasylenko, A. Gzella, R. Lesyk, *Eur. J. Med. Chem.* 45 (2010) 5012-5021.
32. H. N. Hafez, A. R. El-Gazzar, *Bioorg. Med. Chem. Lett.* 19 (2009) 4143-4147.
33. I. Subtel'na, D. Atamanyuk, E. Szymanska, K. Kiec-Kononowicz, B. Zimenkovsky, O. Vasylenko, A. Gzella, R. Lesyk, *Bioorg. Med. Chem.* 18 (2010) 5090-5102.
34. S. Moorkoth, K. Srinivasan, G. N. Kutty, J. Alex, M. Naseer, *Med. Chem. Res.* 22 (2012) 1-12.
35. H. Harnisch, *Liebigs Ann.*, 765 (1973) 8-14.
36. A. Nohara, T. Umetani, Y. Sanno, *Tetrahedron Lett.* ,14 (1973) 1995-1998.
37. H.M. El-Shaer, S.A.-G. Abdel-Aziz, F.I. Hanafy, T.E.-S. Ali, A.Z. El-Fauomy, *Eur. J. Chem.*, 2 (2011) 158-162.
38. A. Dziewulska-Kułaćzkowska, L. Mazur, *J. Mol. Struct.* 985 (2011) 233-242.
39. H. M. Shaaer, *Chem. Papers* 50 (1996) 349-353.

40. A.O. Fitton, J.R. Frost, P.G. Houghton, H. Suschitzky, *J. Chem. Soc., Perkin Trans. 1, 2* (1979) 1691-1694.
41. I.O. Donkor, Y.S. Abdel-Ghany, P.F. Kador, T. Mizoguchi, A. Bartoszko-Malik, D.D. Miller, *Eur. J. Med. Chem.*, 33 (1998) 15-22.
42. A. Husain, *Asian J. Chem.*, 17 (2005) 2055-2057.
43. V.H. Shah, *J. Ind. Chem. Soc.*, 64 (1987) 678-681.
44. J. Finkelstein, *J. Am. Chem. Soc.*, 66 (1944) 407-408.
45. A.W. Ingersoll, S.H. Babcock, *Org. Synth.*, 2 (1943) 328.
46. M. Crawford, W.T. Little, *J. Chem. Soc. (Resumed)*, (1959) 729-731.
47. J. Liu, Y-H. Hui, L-H. Cao, *Chin. J. Org. Chem.*, 26 (2006) 533-536.
48. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, M.R. Boyd, *J. Natl. Cancer Inst.*, 82 (1990) 1107-1112.
49. R.G. Khalifah, *J. Biol. Chem.* 246 (1971) 2561-2573.
50. M. M. Ghorab, F. A. Ragab, H. I. Heiba, R. M. El-Hazek, *Eur. J. Med. Chem.* 46 (2011) 5120-5126.
51. M. M. Ghorab, F. A. Ragab, H. I. Heiba, H. M. Agha, *J. Basic. Appl. Chem.* 1 (2011) 8-14.
52. A. Maresca, D. Vullo, A. Scozzafava, C.T. Supuran, *J. Enzyme Inhib. Med. Chem.* 28 (2013) 388-391.
53. F. Liu, A. Martin-Mingot, F. Lecornué, A. Maresca, S. Thibaudeau, C.T. Supuran *J. Enzyme Inhib. Med. Chem.* 27 (2012) 886-891.
54. R. Demirdağ, E. Yerlikaya, M. Şentürk, Ö.I. Küfrevioğlu, C.T. Supuran, *J. Enzyme Inhib. Med. Chem.* 28 (2013) 278-282.

**Figure captions:**

**Figure 1.** Examples of chromone-sulfonamide hybrids as antitumor and CA inhibitors.

**Figure 2.** General formulae of target compounds.

**Figure 3.** Flow cytometry histograms of MCF-7 and A-549 cells after 24h treatment with **4a**.

**Scheme captions:**

**Scheme 1.** Synthesis of compounds **3a-f** and **4a-f**.

**Scheme 2.** Synthesis of compounds **7a-f**.

**Scheme 3.** Synthesis of compounds **10a-f** and **11a-f**.

**Table captions:**

**Table 1.**  $IC_{50}$  values  $\pm$  SEM of the new compounds against MCF-7 and A-549 cell lines

**Table2.**  $K_i$  values of tested compounds on hCA I, II, IX and XII.

ACCEPTED MANUSCRIPT

Table 1.

Compound	IC <sub>50</sub> (μM) ± SEM MCF-7	IC <sub>50</sub> (μM) ± SEM A-549
3a	22.19±1.01	33.39±6.74
3b	25.80±0.58	57.23±0.63
3c	30.06±1.13	> 100
3d	45.62±1.56	36.35±1.70
3e	48.61±4.10	> 100
3f	28.81±1.57	39.05±1.13
4a	0.72±0.03	0.50±0.02
4b	34.50±1.64	59.66±0.29
4c	> 100	85.25±4.24
4d	93.57±5.71	55.83±2.73
4e	58.61±4.33	25.59±2.70
4f	> 100	> 100
7a	8.91±1.08	2.23±55.91
7b	>100	>100
7c	82.60±7.20	>100
7d	>100	>100
7e	>100	>100
7f	47.10±3.17	>100
10a	11.50±1.19	1.73±40.36
10b	30.01±1.40	>100
10c	>100	40.47±1.84
10d	99.71±5.90	63.21±2.78
10e	88.48±8.25	88.40±3.02
10f	>100	>100
11a	24.31±2.83	13.77±2.08
11b	>100	>100
11c	>100	59.03±7.14
11d	93.92±5.49	52.61±2.47
11e	>100	>100
11f	>100	>100
DOX	33.13±2.90	26.81±2.50

**Table 2.**

Compound	$K_i$ (nM)*			
	hCA I	hCA II	hCA IX	hCA XII
<b>3b</b>	>10000	>10000	23.84	424.04
<b>3d</b>	>10000	>10000	37.62	79.35
<b>3e</b>	>10000	>10000	19.91	22.88
<b>3f</b>	>10000	>10000	20.93	62.02
<b>4a</b>	965.03	370.02	29.75	4.54
<b>4b</b>	>10000	>10000	32.09	10.76
<b>7a</b>	398.78	12.95	14.26	9.91
<b>7c</b>	>10000	>10000	24.74	85.83
<b>7f</b>	>10000	1064.56	25.58	546.55
<b>10a</b>	8003.15	75.22	23.04	5.23
<b>10b</b>	>10000	1112.0	25.24	9.71
<b>11a</b>	>10000	722.05	18.39	6.24
<b>AZA</b>	250.00	12.00	25.00	5.70

**AZA** (Acetazolamide), a well-known CAI, was used as a standard for comparison.

\* Mean from 3 different assays, by a stopped flow technique (errors were in the range of  $\pm 5$ -10 % of the reported values).







Figure 1.




General formula A



General formula B



General formula C



General formula D

Figure 2.






Figure 3.




Scheme 1.

**Reagents and reaction conditions.** **a:** Dry DMF, POCl<sub>3</sub>, overnight; **b:** appropriate sulfonamide, abs. ethanol, drops of gl.acetic acid, 3.5h; **c:** NaBH<sub>4</sub>, abs. ethanol, 24h.



Scheme 2.

**Reagents and reaction conditions.** **a:** chloroacetyl chloride, DMF, RT, 2-4h; **b:**  $\text{NH}_4\text{SCN}$ , ethanol, reflux 3-12h; **c:** compound **2**, gl. acetic acid,  $\text{CH}_3\text{COONa}$  anh., reflux, 3-12h.



Scheme 3.

**Reagents and reaction conditions.** **a:** NaOH solution (10%), stir, 2h; **b:** compound 2, acetic anhydride,  $\text{CH}_3\text{COONa}$  anh., boiling water bath, 5h; **c:** appropriate sulfonamide, gl.acetic acid,  $\text{CH}_3\text{COONa}$  anh., boiling water bath, 8-24h.

**Highlights:**

- Four series of chromone-based sulfonamides were synthesized.
- Cytotoxicity was tested against MCF-7 and A-549 cell lines.
- CA inhibition was assessed against hCA I, II, IX and XII.
- Apoptotic study for the most active compound **4a** was conducted.